US 12,186,277 B2
Peptides and combination of peptides for use in immunotherapy against various cancers
Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Colette Song, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on May 13, 2022, as Appl. No. 17/743,778.
Application 17/743,778 is a continuation of application No. 17/727,255, filed on Apr. 22, 2022.
Application 17/727,255 is a continuation of application No. 17/327,458, filed on May 21, 2021, abandoned.
Application 17/327,458 is a continuation of application No. 16/705,042, filed on Dec. 5, 2019, granted, now 11,433,124.
Application 16/705,042 is a continuation of application No. 16/408,653, filed on May 10, 2019, granted, now 10,525,116, issued on Jan. 7, 2020.
Application 16/408,653 is a continuation of application No. 16/116,323, filed on Aug. 29, 2018, granted, now 10,342,859, issued on Jul. 9, 2019.
Application 16/116,323 is a continuation of application No. 15/374,882, filed on Dec. 9, 2016, granted, now 10,179,165, issued on Jan. 15, 2019.
Claims priority of provisional application 62/266,233, filed on Dec. 11, 2015.
Claims priority of application No. 1521894 (GB), filed on Dec. 11, 2015.
Prior Publication US 2022/0280623 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/72 (2006.01); C07K 14/725 (2006.01); C07K 14/81 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/38 (2006.01); C07K 16/40 (2006.01); C12N 5/0783 (2010.01); C12N 9/02 (2006.01); C12N 9/12 (2006.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G16B 25/00 (2019.01); G16B 25/10 (2019.01); A61K 38/00 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 35/17 (2013.01); A61K 39/4611 (2023.05); A61K 39/4644 (2023.05); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/47 (2013.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/71 (2013.01); C07K 14/721 (2013.01); C07K 14/8135 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C07K 16/2869 (2013.01); C07K 16/30 (2013.01); C07K 16/38 (2013.01); C07K 16/40 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/0091 (2013.01); C12N 9/1264 (2013.01); C12N 15/115 (2013.01); C12Q 1/6886 (2013.01); C12Y 116/01 (2013.01); C12Y 207/07031 (2013.01); G01N 33/57484 (2013.01); G16B 25/00 (2019.02); G16B 25/10 (2019.02); A61K 38/00 (2013.01); A61K 2039/572 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2319/40 (2013.01); C12N 2310/16 (2013.01); C12N 2502/11 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/47 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence ALLGTKILL (SEQ ID NO: 105) in the form of a pharmaceutically acceptable salt.